Search

Your search keyword '"Fantini, Fabrizio"' showing total 157 results
Start Over Author "Fantini, Fabrizio"
157 results on '"Fantini, Fabrizio"'

1. Algorithmic Pricing: Implications for Consumers, Managers, and Regulators

Author

Spann, Martin, primary, Bertini, Marco, additional, Koenigsberg, Oded, additional, Zeithammer, Robert, additional, Aparicio, Diego, additional, Chen, Yuxin, additional, Fantini, Fabrizio, additional, Jin, Ginger Zhe, additional, Morwitz, Vicki, additional, Leszczyc, Peter Popkowski, additional, Vitorino, Maria Ana, additional, Williams, Gizem Yalcin, additional, and Yoo, Hyesung, additional

Published
2024
Full Text
View/download PDF

2. Make dynamic pricing, data granularity a priority

Author

Fantini, Fabrizio

Subjects
Prescription pricing -- Control, Pharmaceutical industry -- Industry sales and revenue, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

America's large chain drug stores have been in a tough spot. Walgreens' fourth quarter report shed light on a whopping $3.1 billion in net losses for the calendar year. Rite [...]

Published
2024

4. How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World: Perspectives from 11 Countries

Author

Sun, Qisi, McMahon, Devon E., Ugwu-Dike, Pearl O., Sun, Qiuning, Tang, Keyun, Zhang, Hanlin, Suchonwanit, Poonkiat, Oh, Choon Chiat, Chong, Alvin H., Willems, Anneliese, Galván, Cristina, Dodiuk-Gad, Roni P., Fantini, Fabrizio, Recalcati, Sebastiano, Avancini, Joao, Miyamoto, Denise, Sanches, Jose A., Raboobee, Noufal, Bravo, Francisco, and Freeman, Esther E.

Published
2021
Full Text
View/download PDF

5. Analytics for Marketers.

Author

Fantini, Fabrizio and Narayandas, Das

Subjects
DATA analysis, MARKETING personnel, ALGORITHMS, ARTIFICIAL intelligence in business, BUSINESS intelligence, INDUSTRIAL efficiency, AUTOMATION, MANAGEMENT
Abstract

Advanced analytics can help companies solve a host of management problems, including those related to marketing, sales, and supply-chain operations, which can lead to a sustainable competitive advantage. But as more data becomes available and advanced analytics are further refined, managers may struggle with when, where, and how much to incorporate machines into their business analytics, and to what extent they should bring their own judgment to bear when making data-driven decisions. In general, humans are better at decisions involving intuition and ambiguity resolution. Machines are far superior at decisions requiring deduction, granularity, and scalability. How can you find the right balance? There are three common approaches to analytics: descriptive, where decisions are made mainly by humans; predictive, which combines aspects of the other two; and prescriptive, which usually means autonomous management by ma- chines. This article describes when and how to use each approach and examines the trade-offs and limitations. Although the focus is on marketing and sales, the principles may be applied more broadly. INSET: The Evolution of Price Markdowns at Event Network. [ABSTRACT FROM AUTHOR]

Published
2023

10. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma

Author

Campana, Luca G, Farronato, Sofia, Hodgetts, Jackie, Odili, Joy, Vecchiato, Antonella, Bracken, Alison, Baier, Susanne, Bechara, Falk G, Borgognoni, Lorenzo, Caracò, Corrado, Carvalhal, Sara, Covarelli, Piero, Clover, James, Eisendle, Klaus, Fantini, Fabrizio, Fierro, Maria Teresa, Farricha, Victor, Gregorelli, Chiara, Hafner, Jürg, Kunte, Christian, Gerlini, Gianni, Hessam, Schapoor, Mandalà, Mario, Piazzalunga, Dario, Quaglino, Pietro, Snoj, Marko, Ross, Alastair Mackenzie, Trigona, Béatrice, Moreno-Ramirez, David, Tauceri, Francesca, Peach, Howard, Rutkowski, Piotr, Muir, Tobian, de Terlizzi, Francesca, Patuzzo, Roberto, Mühlstädt, Michael, Dietrich, Karin-Almut, Mussack, Thomas, Matteucci, Paolo, Kis, Erika, Ascierto, Paolo, Sersa, Gregor, Valpione, Sara, and Stingeni, Luca

Published
2023

11. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma.

Author

Campana, Luca G., Farronato, Sofia, Hodgetts, Jackie, Odili, Joy, Vecchiato, Antonella, Bracken, Alison, Baier, Susanne, Bechara, Falk G., Borgognoni, Lorenzo, Caracò, Corrado, Carvalhal, Sara, Covarelli, Piero, Clover, James, Eisendle, Klaus, Fantini, Fabrizio, Teresa Fierro, Maria, Farricha, Victor, Gregorelli, Chiara, Hafner, Jürg, and Kunte, Christian

Subjects
MELANOMA, DELPHI method, LIKERT scale, QUALITY assurance, DERMATOLOGISTS, COMORBIDITY, MEDICAL audit
Abstract

Background: Skin metastases are an important co-morbidity in melanoma. Despite broad adoption, electrochemotherapy implementation is hindered by a lack of treatment indications, uncertainty regarding procedural aspects, and the absence of quality indicators. An expert consensus may harmonize the approach among centres and facilitate comparison with other therapies. Methods: An interdisciplinary panel was recruited for a three-round e-Delphi survey. A literature-based 113-item questionnaire was proposed to 160 professionals from 53 European centres. Participants rated each item for relevance and degree of agreement on a fivepoint Likert scale, and received anonymous controlled feedback to allow revision. The items that reached concordant agreement in two successive iterations were included in the final consensus list. In the third round, quality indicator benchmarks were defined using a real-time Delphi method. Results: The initial working group included 122 respondents, of whom 100 (82 per cent) completed the first round, thus qualifying for inclusion in the expert panel (49 surgeons, 29 dermatologists, 15 medical oncologists, three radiotherapists, two nurse specialists, two clinician scientists). The completion rate was 97 per cent (97 of 100) and 93 per cent (90 of 97) in the second and third rounds respectively. The final consensus list included 54 statements with benchmarks (treatment indications, (37); procedural aspects, (1); quality indicators, (16)). Conclusion: An expert panel achieved consensus on the use of electrochemotherapy in melanoma, with a core set of statements providing general direction to electrochemotherapy users to refine indications, align clinical practices, and promote quality assurance programmes and local audits. The residual controversial topics set future research priorities to improve patient care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Zwei Welten.

Author

Fantini, Fabrizio and Narayandas, Das

Abstract

Copyright of Harvard Business Manager is the property of manager magazin Verlagsgesellschaft mbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023

16. Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists

Author

Ciuluvica, Cristina, primary, Gualdi, Giulio, additional, Dal Canton, Marco, additional, Fantini, Fabrizio, additional, Paradisi, Andrea, additional, Sbano, Paolo, additional, Simonacci, Marco, additional, Dusi, Daniele, additional, Vezzoni, Gian Marco, additional, D’Acunto, Carmine, additional, Lombardo, Maurizio, additional, Zanchi, Malvina, additional, Alfredo, Zucchi, additional, Eisendle, Klaus, additional, Prignano, Francesca, additional, and Amerio, Paolo, additional

Published
2021
Full Text
View/download PDF

17. The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy

Author

Gualdi, Giulio, primary, Porreca, Annamaria, additional, Amoruso, Giuseppe Fabrizio, additional, Atzori, Laura, additional, Calzavara-Pinton, Piergiacomo, additional, De Tursi, Michele, additional, Buduo, Andrea Di, additional, Marino, Pietro Di, additional, Fabroncini, Gabriella, additional, Fantini, Fabrizio, additional, Fargnoli, Maria Concetta, additional, Giannotta, Gaetano, additional, Lacarruba, Francesco, additional, Lotesoriere, Andrea, additional, Merli, Martina, additional, Micali, Giuseppe, additional, Paradisi, Andrea, additional, Puviani, Mario, additional, Quaglino, Pietro, additional, Rongioletti, Franco, additional, Rubatto, Marco, additional, Sbano, Paolo, additional, Scalvenzi, Massimiliano, additional, Soglia, Simone, additional, Sollima, Laura, additional, Villani, Alessia, additional, Nicola, Marta Di, additional, and Amerio, Paolo, additional

Published
2021
Full Text
View/download PDF

18. Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real‐world clinical experience.

Author

Pezzolo, E., Cazzaniga, S., Di Leo, S., Naldi, L., Altomare, Gianfranco, Annali, Giordana, Antelmi, Annarita, Arancio, Luisa, Calzavara‐Pinton, Piergiacomo, Carabelli, Angelo, Carrera, Carlo, Cattaneo, Angelo, Colombo, Enrico, Daly, Massimo, Dapavo, Paolo, Defilippi, Claudia, Di Mercurio, Marco, Fantini, Fabrizio, Fierro, Maria T, and Fossati, Silvia

Subjects
DIMETHYL fumarate, LATENT tuberculosis, PSORIASIS, PSORIATIC arthritis
Abstract

Patients on DMF had used systemic therapies for psoriasis, including biologics, more frequently than patients under other systemic treatments (73.4% vs. 50.7%, I P i = 0.003). DMF may be the preferred choice for multi-failure psoriasis patients with treatment-emergent side-effects, due to its favourable long-term safety profile. When comparing patients on DMF versus patients under other systemic treatments through cumulative PASI75 up to the first therapy discontinuation, we found, from month 9 onwards, a slightly superior improvement in the DMF group, although without any statistically significant difference (Figure 1). [Extracted from the article]

Published
2022
Full Text
View/download PDF

26. Melanoma Diagnostic Delay: Quantitative and Qualitative Measurement of COVID-19 Lockdown Effect

Author

Gualdi, Giulio, primary, Porreca, Annamaria, additional, Amoruso, Giuseppe Fabrizio, additional, Atzori, Laura, additional, Calzavara-Pinton, Piergiacomo, additional, De Tursi, Michele, additional, Di Buduo, Andrea, additional, Di Marino, Pietro, additional, Fabroncini, Gabriella, additional, Fantini, Fabrizio, additional, Fargnoli, Maria Concetta, additional, Giannotta, Gaetano, additional, Lacarruba, Francesco, additional, Lotesoriere, Andrea, additional, Merli, Martina, additional, Micali, Giuseppe, additional, Paradisi, Andrea, additional, Puviani, Mario, additional, quaglino, pietro, additional, Rongioletti, Franco, additional, Rubatto, Marco, additional, Sbano, Paolo, additional, Scalvenzi, Massimiliano, additional, Soglia, Simone, additional, Sollima, Laura, additional, Villani, Alessia, additional, Di Nicola, Marta, additional, and Amerio, Paolo, additional

Published
2020
Full Text
View/download PDF

27. When basal cell carcinomas became giant: an Italian multicenter study

Author

Gualdi, Giulio, primary, Monari, Paola, additional, Calzavara‐Pinton, Piergiacomo, additional, Caravello, Simone, additional, Fantini, Fabrizio, additional, Bornacina, Carlo, additional, Specchio, Francesca, additional, Argenziano, Giuseppe, additional, Simonetti, Vito, additional, Caccavale, Stefano, additional, La Montagna, Maddalena, additional, Cecchi, Roberto, additional, Landi, Christian, additional, Simonacci, Marco, additional, Dusi, Daniele, additional, Puviani, Mario, additional, Zucchi, Alfredo, additional, Zampieri, Pierfrancesco, additional, Inchaurraga, Maria A. G., additional, Savoia, Francesco, additional, Melandri, Davide, additional, Capo, Alessandra, additional, and Amerio, Paolo, additional

Published
2019
Full Text
View/download PDF

34. Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI).

Author

Fania, Luca, Massone, Cesare, Cusano, Francesco, Fantini, Fabrizio, Dellambra, Elena, Samela, Tonia, Passarelli, Francesca, Morese, Roberto, Tartaglione, Tommaso, Maggiore, Marino, Gentile, Piercarlo, Osti, Mattia Falchetto, Sampogna, Francesca, Pallotta, Sabatino, Abeni, Damiano, Marchetti, Paolo, and Naldi, Luigi

Subjects
SKIN cancer, PRECANCEROUS conditions, INTEGRATIVE medicine, BASAL cell carcinoma, ACTINIC keratosis, MEDICAL quality control, DERMATOLOGISTS
Abstract

The term non-melanoma skin cancer (NMSC) refers to skin cancer different from melanoma, and it is usually restricted to basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and their pre-cancerous lesions, e.g., actinic keratosis. These conditions represent the most frequent tumors in Caucasians and are characterized by an increasing incidence worldwide and a high socio-economic impact. The term Integrated Care Pathway (ICP) refers to "a complex intervention for the mutual decision making and organization of care processes for a well-defined group of patients during a well-defined period". The purpose of this paper is to present a proposal from the Italian Association of Hospital Dermatologists (ADOI) for an ICP organization of care of NMSC, considering the hub-and-spoke model in the different geographical areas. This proposal is based on the most recent literature and on documents from the Italian Association of Medical Oncology (AIOM), the European consensus-based interdisciplinary guidelines from the European Association of Dermato-Oncology (EADO), and the National Comprehensive Cancer Network (NCCN). We initially discuss the NMSC outpatient clinic, the role of the multidisciplinary working groups, and the hub-and-spoke model regarding this topic. Then, we define the ICP processes specific for BCC and SCC. The ICP for NMSC is an innovative strategy to guarantee the highest possible quality of health care while the hub-andspoke model is crucial for the organization of different health care structures. Considering the importance on this topic, it is essential to create a valid ICP together with an efficient organization within the different geographical areas. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. When basal cell carcinomas became giant: an Italian multicenter study.

Author

Gualdi, Giulio, Monari, Paola, Calzavara‐Pinton, Piergiacomo, Caravello, Simone, Fantini, Fabrizio, Bornacina, Carlo, Specchio, Francesca, Argenziano, Giuseppe, Simonetti, Vito, Caccavale, Stefano, La Montagna, Maddalena, Cecchi, Roberto, Landi, Christian, Simonacci, Marco, Dusi, Daniele, Puviani, Mario, Zucchi, Alfredo, Zampieri, Pierfrancesco, Inchaurraga, Maria A. G., and Savoia, Francesco

Subjects
BASAL cell carcinoma, SOCIOCULTURAL factors, SOCIAL history, SOCIAL factors, SOCIAL accounting, BASAL cell nevus syndrome
Abstract

Background: Giant basal cell carcinoma (GBCC) is a basal cell carcinoma (BCC) enlarged in a diameter more than 5 cm. Since GBCCs are a highly infrequent entity and the occurrence rate is approximately 0.5–1% out of all BCC types, only anecdotal cases are reported, and causes and characteristics inducing development of this tumor are not defined. Objectives: Evaluate causative factors and clinico‐histological characteristics of GBCCs. Methods: The study is a 6‐month, hospital‐based case series study performed in 12 Italian dermatologic centers. Results: A total of 59 cases and 458 control BCCs were collected. No significant differences existed between the two groups if we take into account social or cultural factors. The average duration of GBCCs is considerably longer than controls. GBCCs are located on unexposed areas while BCCs are on areas not usually covered by clothes. Superficial histological subtype was more frequent in the BCCs group, while infiltrative in GBCCs. GBCCs showed significantly higher local invasiveness, and greater metastatic capacity. More than half of GBCCs had been previously treated with one or more treatments. Conclusions: Patients with GBCCs appear to belong to two categories: (i) those who present with GBCC due to delay in accessing medical attention, and (ii) those who have BCCs previously treated with inappropriate strategies. Only very few cases can be carried out with intrinsic biological features of tumor aggressiveness. Social and cultural conditions do not appear to be involved in the development of GBCCS. These observations may help clinicians in selecting correct therapeutic strategies in the treatment of BCCs, which give rise to GBCC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Reply

Author

Fantini, Fabrizio, primary, Kovacs, Emese, additional, and Scarabello, Alessandra, additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results